Pneumonia Vaccination – More Dangerous in Elderly

READ BEFORE ENTERING; This website is for information purposes only; This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of Top-life coach or its staff.

The Pneumonia Vaccination. A look deeper into the vaccine the way your doctor does not do.

We will also give you some information on the flu vaccination since you may also want some facts. The list of detrimental side effects of these two vaccinations is profound. You can see an abundance of evidence that the flu and pneumonia vaccines are very ineffective over the age of 65 yet still carry all the horrific potential side effects.

Keep in mind that when you read the words “rare side-effects,” their definition is 10% or less. A side effect of these vaccines varies from mild to death. Since they are not effective, you can decide for yourself if you want to take the risk.

Your pharmaceutically trained doctor who went to a pharmaceutically owned university makes a living prescribing pharmaceuticals so that they will have an extremely biased opinion. We encourage you to gather factual information from reliable sources and think for yourself. Below are some highlights of some science with links to the articles and studies for you to read.

There is an abundance of evidence of widespread manipulation of conclusions in studies. It would help if you also read who funded the studies and what the connection to pharma is.

Studies not funded or connected to pharma for-profit show significant differences in conclusions.

Pneumonia immunization in older adults: a review of vaccine effectiveness and strategies

From the ABSTRACT:  The effectiveness of this strategy in preventing pneumonia has been in doubt despite the increase in vaccination coverage among older adults. The presence of selection bias and the use of nonspecific endpoints in these studies make the current evidence inconclusive in terms of overall benefit.

Simonsen et al. (3) analyzed influenza vaccine coverage and computed influenza-related mortality and all-cause deaths for 33 influenza seasons from 1968 to 2001 in the USA elderly population. The study found no correlation between increasing vaccination coverage after 1980 and declining mortality rates in any age group. Moreover, Simonsen and colleagues 3,79 argued that flu shots could not possibly have prevented more deaths than the 5%–10% of deaths that were flu-related. Assuming vaccine effectiveness of 50% against these winter deaths with no deaths attributable to influenza outside the winter months, the maximum percentage of all-cause winter mortality that could be prevented by the influenza vaccine would be about 2%–5%. Changes of such a small magnitude in all-cause deaths could easily be missed in ecological and observational studies.

From the CONCLUSION: Current US strategies to prevent pneumonia among older adults include recommending immunization with PPV and annual influenza vaccinations. However, the effectiveness of these vaccines decreases with increasing age and among individuals with comorbid conditions.

It should be noted that vaccination do NOT reduce pneumonia. A meta-analysis shows no decrease in pneumonia incidence as a result of vaccination.

We could not correlate increasing vaccination coverage after 1980 with declining mortality rates in any age group. Because fewer than 10% of all winter deaths were attributable to influenza in any season, we conclude that observational studies substantially overestimate vaccination benefit.

Pneumococcal vaccination in adults: Does it really work?

PPV does not appear to be particularly effective in preventing pneumonia, even in populations for whom the vaccine is currently recommended. It is also uncertain whether PPV could affect the severity of the disease or the mortality rate.

Pneumococcal Vaccine: Vaccinate! Revaccinate?

Older and ill patients are those that revaccination is recommended, yet they respond least well to the vaccine (serologically). Age 65 is arbitrary. There are worse responses and a shorter length of efficacy with increasing age. We say to revaccinate high-risk patients; however, high-risk people respond least well to the vaccine and the shortest period of time.

There were no differences between vaccination rates among bacteremic patients (29 percent) and control patients (24 percent).

If the vaccine were protective, vaccination rates should be higher among the control patients, and serotype distribution should be different in vaccinated and nonvaccinated bacteremic patients. There were no differences between vaccination rates among bacteremic patients (29 percent) and control patients (24 percent). Furthermore, 65 percent of the blood isolates from nonvaccinated bacteremic patients were serotypes included in the vaccine compared with 69 percent of the isolates in vaccinated bacteremic patients. The pneumococcal vaccine did not appear to be protective in this high-risk population.

Efficacy of pneumococcal vaccine in high-risk patients

We were unable to demonstrate any pneumococcal vaccine’s efficacy in preventing pneumonia or bronchitis in this population. Our data suggest that chronically ill patients, who are most susceptible to infection, may have an impaired immune response to the pneumococcal vaccine.

Pneumonia Vaccine Side Effects

Post-Marketing Experience

The following list of adverse reactions includes those identified during post-approval use of PNEUMOVAX 23. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or their causal relationship to product exposure.

General disorders and administration site conditions
Fever (>102°F)
Warmth at the injection site
Decreased limb mobility
Peripheral edema in the injected extremity
Digestive System
Thrombocytopenia in patients with stabilized idiopathic thrombocytopenic purpura{3}
Hemolytic anemia in patients who have had other hematologic disorders
Hypersensitivity reactions including
Anaphylactoid reactions
Serum Sickness – (generally rash, joint stiffness, fever)
Angioneurotic edema (swelling of areas beneath the skin, deep layers)
Musculoskeletal System
Arthralgia – (joint pain)
Nervous System
Paresthesia – (pins and needle sensation)
Radiculoneuropathy – (pain, numbness, weakness arms and legs)
Guillain-Barré syndrome – (Immune system attacks the nerves – Paralysis can occur in GB Syndrome)
Febrile convulsion
Cellulitis-like reactions
Erythema multiforme – bullseye shaped lesions
Increased serum C-reactive protein

Studies of group A and C meningococcal polysaccharide vaccine and repeated doses of PPV23 in adults and children have shown that a state of immune tolerance, or hyporesponsiveness, can develop to repeated polysaccharide vaccine antigen exposures.

Pneumococcal Vaccine
(click for package insert)
(not in order of quantity; see package insert for quantities)
Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

*This vaccine has been discontinued.

Wyeth Pharmaceuticals Inc.
Mar. 2009
soy peptone broth, casamino acids and yeast extract-based medium, ammonium sulfate, saccharides aluminum (as aluminum phosphate adjuvant)
Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Prevnar 13
Wyeth Pharmaceuticals Inc.
soy peptone broth, casamino acids and yeast extract-based medium, ammonium sulfate, CRM 197 polysorbate 80, succinate buffer, aluminum (as aluminum phosphate adjuvant)
Pneumococcal Vaccine, Polyvalent
Merck & Co., Inc.
May 2014
isotonic saline solution, phenol

Vaccine Ingredients

Aluminum — “I have to change my mind that aluminum has a role in autism. I believe it now does.” –Dr. Chris Exley, 2017

Experimental research, however, clearly shows that aluminum adjuvants have a potential to induce serious immunological disorders in humans. In particular, aluminum in adjuvant form carries a risk for autoimmunity, long-term brain inflammation and associated neurological complications and may thus have profound and widespread adverse health consequences. In our opinion, the possibility that vaccine benefits may have been overrated and the risk of potential adverse effects underestimated, has not been rigorously evaluated in the medical and scientific community.

Soy Peptone Broth — The next allergy to usually show up at about 3 months of age is soy allergy due to the soy peptone broth and aluminum adjuvant in the Pneumococcal Conjugate vaccine given at approximately 2 months of age.

Polysorbate 80 — It is obvious that there is a glaring lack of basic science research into the toxic effects of the vaccine ingredient, Polysorbate 80, on human health. Polysorbate 80 is used in pharmacology to assist in the delivery of certain drugs or chemotherapeutic agents across the blood-brain-barrier.8 

The flu vaccine was not effective in protecting adults over 65 years old against the flu

U.S. health officials released data showing last year’s flu vaccine was 42% effective at preventing flu infections serious enough to send a person to the hospital — but it did not work for certain age groups.

Last year’s flu vaccine had no clear effect in adults over 65, or adults 18-49 years old, although it was 60% effective in young children.

The Flu vaccine effectiveness has averaged about 46% over the last 10 years in the United States.

Flu vaccines cause fevers in 1-2% of people in all age groups, but younger children are more likely to develop high fevers which lead to seizures but back to sixty-five and over.

Shoulder Injury Related to Vaccine Administration (SIRVA) is a rare side effect of the flu shot. It occurs when the needle punctures the bursa, tendons, or ligaments in the shoulder. SIRVA can cause chronic shoulder pain and permanent limited mobility that causes disability.

What are the side effects of the flu vaccine?

The risk depends on the vaccine, but the following is a list of severe side effects that have been reported with flu vaccines:

  • Anaphylaxis
  • Anaphylactic shock
  • Angioedema
  • Arthritis
  • Asthma
  • Bell’s palsy
  • Brachial plexus neuropathy
  • Brain damage
  • Cellulitis
  • Coma
  • Convulsions
  • Cranial nerve paralysis
  • Death
  • Encephalopathy
  • Encephalomyelitis
  • Erythema multiforme
  • Extensive limb swelling
  • Febrile seizures
  • Fever
  • Flu-like illness
  • Fainting
  • Infection
  • Guillain-Barré Syndrome
  • Meningitis
  • Microscopic polyangiitis
  • Migraine headache
  • Myelitis
  • Nerve damage (neuropathy)
  • Neuralgia
  • Neurological disorders
  • Numbness and tingling
  • Optic neuritis
  • Paresthesia
  • Paralysis
  • Partial facial paralysis
  • Rash
  • Respiratory distress
  • Seizure
  • Serum sickness
  • SIRVA (Shoulder Injury Related to Vaccine Administration)
  • Skin reactions
  • Spinal cord inflammation
  • Stevens-Johnson Syndrome
  • Syncope and pre-syncope (fainting)
  • Tachycardia
  • Thrombocytopenia
  • Tonic-clonic limb movements
  • Transverse myelitis
  • Upper respiratory tract infection
  • Vasculitis with transient kidney involvement
  • Vision problems

Pneumovax 23 – Protective efficacy varied in studies between  45% and 92%

The CDC is now recommending Prevnar 13 first, followed by Pneumovax 23 six to 12 months later.

Prevnar 13 – Serious Adverse Experiences

In this study, 10 subjects had serious adverse experiences within 14 days of vaccination: 6 who received PNEUMOVAX 23 and 4 who received placebo. Serious adverse experiences within 14 days after PNEUMOVAX 23 included angina pectoris, heart failure, chest pain, ulcerative colitis, depression,
and headache/tremor/stiffness/sweating. Serious adverse experiences within 14 days after the placebo included myocardial infarction complicated with heart failure, alcohol intoxication, angina pectoris, and edema/urinary retention/heart failure/diabetes.
Five subjects reported serious adverse experiences that occurred outside the 14-day follow-up window: 3 who received PNEUMOVAX 23 and 2 who received placebo. Serious adverse experiences after PNEUMOVAX 23 included cerebrovascular accident, lumbar radiculopathy, and
pancreatitis/myocardial infarction resulting in death. Serious adverse experiences after the placebo included heart failure and motor vehicle accident resulting in death.

Testing Adjuvants in Pneumonia Vaccinations

167 healthy subjects were randomized to receive two doses (days 0 and 60) of 10 or 30 μg PhtD-dPly plus AS02V or alum, 8PCV plus AS02V or alum, or one dose (day 0) of 23-valent polysaccharide pneumococcal vaccine (23PPV) as a control (placebo on day 60). The safety, reactogenicity, and antibody-specific responses to these vaccines were evaluated. No vaccine-related serious adverse events were reported.

GlaxoSmithKline Biologicals S.A. was the funding source and was involved in all stages of study conduct and analysis. GlaxoSmithKline Biologicals S.A. also funded all costs associated with the development and the publishing of this article. All authors had full access to the data, and the corresponding author was responsible for submitting the publication

From the Package Insert of Merck’s PNEUMOVAX 23

Since elderly individuals may not tolerate medical interventions, as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals, cannot be ruled out.  Post-marketing reports have been received in whichsome elderly individuals had severe adverse experiences and a complicated clinical course following vaccination.

Some individuals with underlying medical conditions of varying severity experienced local reactions and fever associated with clinical deterioration requiring hospital care. Yet they give you no details.

Here is a Data Sheet that states it a little more dramatically:

Use in the elderly – Post-marketing reports have been received in which some frail elderly individuals with multiple co-morbid conditions had severe adverse experiences and a complicated clinical course following vaccination. Yet they still give you no details.

And here is a different story:

No overall difference in safety was observed between these subjects and younger subjects.

From, Persons 65 years of age or older were enrolled in several conducted pre-and post-licensure. In the largest of these studies, the safety of Pneumovax 23 in adults 65 years of age and older as compared to the safety of Pneumovax 23 in adults 50 to 64 years of age. Of 1007 subjects enrolled in this study, 433 subjects were 65 to 74 years of age, and 195 subjects were 75 years of age or older. No overall difference in safety was observed between these subjects and younger subjects.

All Principal Investigators ARE employed by the organization sponsoring the study.

We find it interesting that 10 participants were given a single dose of PNEUMOVAX, but 0/11 (0.00%) were affected or at risk. Events were collected by non-systematic assessment.

Older Group (60-89) PNEUMOVAX Total
3/33 (9.09%)

Acute Coronary Syndrome    1/33 (3.03%)Lynch Syndrome – 1/33 (3.03%) – Hereditary non-polyposis colorectal cancer

Bladder Cancer Recurrence – 1/33 (3.03%)

Older Group (60-89)PREVNAR 

Total 2/33 (6.06%)

Cebralvascual accident – 1/33 (3.03%) Stroke

Arthralgia – 1/33 (3.03%) Joint pain

They promote heart disease but say you should absolutely get the vaccination. 

Package Insert of the Pneumonia Vaccine

The package inserts explain that the elderly can have severe and or long-term adverse side effects, yet they do not give you any details. How are you supposed to understand the risks if you are over 65 before considering a pneumonia shot?

They do not say what reactions occurred or how many. They only tell you the most common. Why do they leave out the details you would need to decide if it is worth the risk?

The rate of vaccine-related systemic adverse experiences was higher following revaccination (33.1%) than following primary vaccination (21.7%) in subjects ≥65 years of age and was similar following revaccination (37.5%) and primary vaccination (35.5%) in subjects 50-64 years of age. The most common systemic adverse experiences reported after PNEUMOVAX 23 were as follows: asthenia/fatigue, myalgia, and headache.

Where are the severe or long term side effects for those 65 and older? Not on the package insert.  They tell you about them but do not give you details and we are dealing with big pharma so we know deception is involved.

This is listed on the insert:


Persons with Moderate or Severe Acute Illness Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.  Persons with Severely Compromised Cardiovascular or Pulmonary Function Caution and appropriate care should be exercised in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.


 Use caution and appropriate care for individuals with severely
compromised cardiovascular and/or pulmonary function in whom
a systemic reaction would pose a significant risk. (5.2)

Vaccines for preventing influenza in healthy adults.


Influenza vaccines have a modest effect in reducing influenza symptoms and working days lost. There is no evidence that they affect complications, such as pneumonia, or transmission.

WARNING: This review includes 15 out of 36 trials funded by industry (four had no funding declaration). An earlier systematic review of 274 influenza vaccine studies published up to 2007 found industry-funded studies were published in more prestigious journals and cited more than other studies independently from methodological quality and size.

Studies funded from public sources were significantly less likely to report conclusions favorable to the vaccines. The review showed that reliable evidence on influenza vaccines is thin but there is evidence of widespread manipulation of conclusions and spurious notoriety of the studies. The content and conclusions of this review should be interpreted in light of this finding.

Vaccines for the Elderly – You Decide Now that You Have Facts

This website is for information purposes only; we are not diagnosing, treating, curing, mitigating, or preventing any disease or medical condition by providing the information contained herein. Before beginning any natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.